Nutrition Status, BMD, and SSRIs
Terminated
- Conditions
- BMD
- Interventions
- Diagnostic Test: Dual-Energy X-ray Absorptiometry (DXA)
- Registration Number
- NCT03383861
- Lead Sponsor
- University of New Mexico
- Brief Summary
The association between selective serotonin reuptake inhibitor (SSRI) use and bone mass density (BMD) has been debated. Some have suggested features of depression, which SSRIs are prescribed to treat, may be a cause of decreased BMD, such as poor overall food intake at the time of SSRI use. Our study seeks to determine whether SSRI use in adults is associated with lower than average BMD, and if there is an association between low micronutrient intake, SSRI use, and a low BMD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 13027
Inclusion Criteria
- Included adult NHANES participants are those who participated in the Dual-Energy X-ray Absorptiometry (DXA) femur-neck BMD test and responded in full to the demographic, pharmaceutical, and dietary surveys.
Exclusion Criteria
- Pregnancy, incomplete survey responses, incomplete DXA results
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Non-user Dual-Energy X-ray Absorptiometry (DXA) Adults, 12,372 non-users, were identified in the National Health and Nutrition Examination Survey (NHANES) data. SSRI long-term user Dual-Energy X-ray Absorptiometry (DXA) Adults, 655 with an SSRI prescription ≥180 days and identified in the National Health and Nutrition Examination Survey (NHANES) data.
- Primary Outcome Measures
Name Time Method BMD t-score NHANES DXA measurement taken 2005-2014
- Secondary Outcome Measures
Name Time Method